On our screens:Cheap stocks by free cash flow yield
What is the market doing?
What the tape says about NBIX
Neurocrine Biosciences, Inc. is +17% over the past year while the S&P 500 is +20%: 3.9 points behind the market.
+17%
1-year return · S&P 500 +20%
- vs 200-day average
- +6.3%
vs 200-day average · close to trend
- RSI (14)
- 52
RSI (14) · neutral
- Below its 52-week high
- 15%
Below its 52-week high
Details›
- Last close2026-09-08
- $155.12
- 1 monthS&P 500 −0.30%
- −2.9%
- 1 yearS&P 500 +20%
- +17%
- 5 yearsS&P 500 +85%
- +80%
- vs 50-day average$162.69
- −4.7%
- 52-week high
- $182.85
- 52-week low
- $123.10
- Annualised volatility
- 37%
| Year | Return |
|---|---|
| 2026 (year to date) | +9.4% |
| 2025 | +3.9% |
| 2024 | +3.6% |
| 2023 | +10% |
| 2022 | +40% |
| 2021 | −11% |
| 2020 | −11% |
| 2019 | +51% |
| 2018 | −8.0% |
| 2017 | +100% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +5.1% |
| Feb | 10 | 2 of 10 | −4.1% |
| Mar | 10 | 3 of 10 | −0.84% |
| Apr | 10 | 2 of 10 | +0.65% |
| May | 10 | 7 of 10 | +7.2% |
| Jun | 10 | 8 of 10 | +2.4% |
| Jul | 11 | 8 of 11 | +4.2% |
| Aug | 11 | 7 of 11 | +3.6% |
| Sep | 11 | 7 of 11 | −1.5% |
| Oct | 10 | 7 of 10 | +1.1% |
| Nov | 10 | 7 of 10 | +2.4% |
| Dec | 10 | 5 of 10 | −2.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers - Specialty & Generic
Ranks #1 of 29 by Smart Score